Applying a simple model of clinical and demographic features associated with GBA mutation carrier status could help target genetic testing in patients with Parkinson s disease, suggests a new study.
Acadia Pharma (ACAD) Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren s NNZ-2591 in Rett Syndrome and Fragile X Syndrom streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Acadia Pharma (ACAD) Announces Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER Study Evaluating DAYBUE in Patients with Rett Syndrome streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Statistically significant differences demonstrated between DAYBUE™ and placebo on efficacy endpoints relevant to Rett syndrome suggest treatment potentially capable of modifying core. | June 8, 2023
Acadia Pharmaceuticals Inc. today announced that four posters in Rett syndrome will be presented at the upcoming American Academy of Neurology annual meeting, being held April 22 – 27, 2023. | April 20, 2023